Keywords: r-pr, sought, take, advantage, says, fisons, its
R-PR Has Sought To Take Advantage, Says Fisons
Article | 11 September 1995
In its defence document against the proposed 240 pence ($3.72) per share offer from Franco-American drug group Rhone-Poulenc Rorer (Marketletter September 4), UK-based ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- Encouraging results with Sangamo's SB-728-T in HIV treatment
- Boehringer Ingelheim transitions to propellant-free Combivent Respimat; names new BMD member
- Bristol-Myers' data on Yervoy and nivolumab causes a stir
- Sanofi prepares for regulatory filing of MF candidate on positive JAKARTA study results
- Neovacs moving forward in rheumatoid arthritis, say analysts
